🔗 Share this article

A shadow economy for unapproved weight-loss drugs is being driven by social media fitness personalities and vendors on communication apps, based on recent findings.

Investigational Drug Gaining Traction Via Social Media

Retatrutide, which remains in research studies, is being promoted by social media influencers for its supposed weight-reducing effects. Followers are urged to contact these accounts directly for supplier links, while also obtaining promotional offers.

Active Commerce on Social Networks

Separately, a flourishing trade exists on messaging services, where groups with thousands of members share comparison images, administration instructions and claims of rapid UK delivery. Sellers promote the substance there before redirecting customers to WhatsApp for transactions.

Understanding Retatrutide

This medication is an experimental injection created by American pharmaceutical company Eli Lilly. The drug targets three gut hormones – glucagon-like peptide-1, GIP and pancreatic hormone. Early trials indicate it could help patients lose up to a quarter of their body weight. Nicknamed the “triple G”, the substance is being hailed digitally as the successor to Ozempic.

Healthcare Experts Voice Worries

Nevertheless, doctors and pharmacists have warned that the distribution of what is still an unlicensed drug in the UK is a cause for concern and could lead to users administering substances of uncertain source.

Several professionals said the demand for retatrutide could be linked to the rising cost of licensed weight loss treatments such as Mounjaro.

Regulatory Position and Implementation

Marketing the unapproved drug on social media or messaging apps is prohibited in the United Kingdom, as it is an unapproved drug that cannot be promoted or supplied for human use under the British medical regulations.

Some influencers try to sidestep the regulations by referring to the substance as a “research chemical” or describing it as “not for human consumption”. The substance is not a controlled drug, but advertising and supply can still violate pharmaceutical, advertising, and customer regulations, potentially leading to penalties, legal action or imprisonment.

Service Response and Content Elimination

Based on the social media company, the service has taken down problematic content and banned associated keywords and search suggestions. The organization said it was committed to maintaining the service secure and investing in enhancing enforcement strategies.

Online Trading Activities

Research also found communities with up to 9,000 participants marketing the experimental drug using Telegram's built-in discovery tool, which functions like a public directory. Typing “retatrutide” immediately brings up channels with thousands of users, filled with photos of slimming results, glowing testimonials and detailed guides for preparing or injecting at home.

After minutes of joining one group, a seller posted contact information, where the majority of purchases occur. The vendor provided an guidebook and promised delivery within 48 hours. When asked whether the substance was authentic, one seller said: “You can’t be sure.” Another provided a photo of a supposed laboratory certificate. None asked about body mass, health issues or previous experience.

Item Information and Pricing

Within these communities, posts display dark colored parcels with Royal Mail stickers, stating to contain new batches. One communication stated: “It took eight of us to load them this morning.”

Buyers can choose between powder vials, mixed at residence with purified liquid, or ready-to-use pens typically priced at £160 for 20mg. When questioned how long a injector should be used, vendors give conflicting answers varying between a few weeks to “depends on your body”.

Service Oversight and Safety Actions

A spokesperson for the messaging service stated it regularly moderated dangerous material on its service including material that encouraged the “misuse of controlled medications”. The organization added that it removed “millions of pieces of harmful content each day”.

Healthcare Professional Warnings

“Individuals are administering substances they can’t verify. Although the science behind this drug is sound, these online products may not include what they advertise,” said Jason Murphy, the director of pharmacy at Chemist4U.

A medical professional of an online medical service connected the surge in interest to recent price rises for authorized slimming drugs such as Mounjaro. “With prices increasing, patients are using social media. But counterfeit treatments are highly risky. You can’t be certain what’s contained or whether the environment they were made in was sterile,” she explained.

Her staff has already seen individuals harmed by self-injection from unconfirmed sources. “We understand the disappointment, but purchasing from messaging apps or WhatsApp is taking chances with your well-being,” stated the doctor. “These materials could be contaminated or incorrectly dosed.”

Manufacturer Statement

A spokesperson from the pharmaceutical company stated retatrutide was in phase 3 research studies and had not been evaluated or authorized by any regulatory agency globally. “Consequently at this point no one can market [it] for human use,” they explained, adding that any item “falsely representing itself as a company experimental product not yet approved … may expose users to potentially significant medical dangers”.